Non-transferrin bound iron in Thalassemia: Differential detection of redox active forms in children and older patients

Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron

(2010) R.C. Hider et al.   Annals of the New York Academy of Sciences

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes

(2010) Peter L. Greenberg et al.   LEUKEMIA RESEARCH

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone

(2010) Patricia Evans et al.   Translational Research

Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron

(2009) Andre M.N. Silva et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Daily labile plasma iron as an indicator of chelator activity inThalassaemia majorpatients

(2009) Giuliana Zanninelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease

(2009) John B. Porter   HEMOGLOBIN

High nontransferrin bound iron levels and heart disease in thalassemia major

(2008) Antonio Piga et al.   AMERICAN JOURNAL OF HEMATOLOGY

Non-transferrin bound iron measurement is influenced by chelator concentration

(2008) A.M. Kolb et al.   ANALYTICAL BIOCHEMISTRY

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia

(2008) Shahina Daar et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The antioxidant properties of serum albumin

(2008) Marjolaine Roche et al.   FEBS LETTERS